Telo Therapeutics, Inc.
San Francisco, US · Founded 2015 · Delaware corporation · 2 employees on LinkedIn · 1 known investors
Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
Founders & leadership
Telo Therapeutics, Inc. was founded in 2015 by Rob Bell.
Board
RG
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.7M disclosed across 1 round · 2021
▶$4.7MraisedJun 2022 · 12 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJun 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. BlazejDirector
- Robert BellExecutive Officer, Director
- Joseph CostelloDirector
- Michael D. TaylorDirector
- Offering amount
- $10.2M
- Amount sold
- $4.7M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapDialectic Therapeutics22 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Solu20 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Applied Therapeutics16 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Relay15 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Companies competing with Telo Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Telo Therapeutics, Inc. do?
- Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
- Who founded Telo Therapeutics, Inc.?
- Telo Therapeutics, Inc. was founded by Rob Bell in 2015.
- Who are Telo Therapeutics, Inc.'s investors?
- Telo Therapeutics, Inc.'s investors include Mission Biocapital.
- How much funding has Telo Therapeutics, Inc. raised?
- Telo Therapeutics, Inc. has disclosed $4.7M raised across 1 round.
- Where is Telo Therapeutics, Inc. headquartered?
- Telo Therapeutics, Inc. is headquartered in San Francisco, US.